<form id="lwufo"><acronym id="lwufo"></acronym></form>
          Log in
          Forgot password ?
          Become a member for free
          Sign up
          Sign up
          New member
          Sign up for FREE
          New customer
          Discover our services
          Dynamic quotes 

          MarketScreener Homepage  >  Equities  >  Italian Stock Exchange  >  DiaSorin S.p.A.    DIA   IT0003492391

          DIASORIN S.P.A.

          News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

          DiaSorin S.p.A. : Close to a key resistance level

          share with twitter share with LinkedIn share with facebook
          05/15/2020 | 04:48am EDT
          long trade
          Target price hit
          Entry price : 179.7€ | Target : 204.38€ | Stop-loss : 144.5€ | Potential : 13.73%
          DiaSorin S.p.A. shares are trading close to a resistance zone which currently limits any upside potential. We expect that this level will be broken due to the stock's technical chart pattern.
          Investors have an opportunity to buy the stock and target the € 204.38.
          DiaSorin S.p.A. : DiaSorin S.p.A. : Close to a key resistance level
          • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

          • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
          • Thanks to a sound financial situation, the firm has significant leeway for investment.
          • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
          • The stock is in a well-established, long-term rising trend above the technical support level at 123.8 EUR

          • The company's "enterprise value to sales" ratio is among the highest in the world.
          • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.75 times its estimated earnings per share for the ongoing year.
          • The company is not the most generous with respect to shareholders' compensation.
          • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
          Stocks mentioned in the article
          ChangeLast1st jan.
          AMP LIMITED -1.72% 1.71 End-of-day quote.-10.70%
          BYD COMPANY LIMITED -8.87% 72.45 End-of-day quote.86.49%
          DIASORIN S.P.A. -3.90% 162.7 Delayed Quote.40.99%
          THE NEW HOME COMPANY INC. -2.52% 4.25 Delayed Quote.-8.80%
          WORLD CO., LTD. -1.33% 1409 End-of-day quote.-47.64%

          Nicolas Aleksy
          ?MarketScreener.com 2020
          share with twitter share with LinkedIn share with facebook

          Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
          The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

          Sales 2020 867 M 1 011 M 1 011 M
          Net income 2020 225 M 263 M 263 M
          Net cash 2020 288 M 335 M 335 M
          P/E ratio 2020 40,0x
          Yield 2020 0,79%
          Capitalization 8 909 M 10 362 M 10 385 M
          EV / Sales 2019
          EV / Sales 2020 9,94x
          Nbr of Employees 1 950
          Free-Float 40,3%
          Upcoming event on DIASORIN S.P.A.
          Income Statement Evolution
          Mean consensus UNDERPERFORM
          Number of Analysts 8
          Average target price 147,56 €
          Last Close Price 162,70 €
          Spread / Highest target 18,3%
          Spread / Average Target -9,30%
          Spread / Lowest Target -37,9%
          EPS Revisions
          Carlo Rosa Chief Executive Officer, Executive Director & GM
          Gustavo Denegri Chairman
          Piergiorgio Pedron Chief Financial Officer & Senior Corporate VP
          Chen Menachem Even Executive Director & Chief Commercial Officer
          Franco Moscetti Independent Director
          Sector and Competitors
          1st jan.Capitalization (M$)
          DIASORIN S.P.A.40.99%10 362
          BIOMÉRIEUX62.95%17 715
          AUTOBIO DIAGNOSTICS CO., LTD.62.67%9 620
          10X GENOMICS, INC.24.13%9 310